Search Results - "Mileshkin, L"

Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older.

Authors: Mileshkin, L. R. Seymour, J. F. Wolf, M. M. et al.

Source: Leukemia & Lymphoma. Nov2005, Vol. 46 Issue 11, p1575-1579. 5p. 4 Charts, 2 Graphs.

Rapid screening for depression--validation of the Brief Case-Find for Depression (BCD) in medical oncology and palliative care patients.

Authors: Jefford, M. Mileshkin, L. Richards, K. et al.

Source: British Journal of Cancer. 8/31/2004, Vol. 91 Issue 5, p900-906. 7p.

A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma.

Authors: Mileshkin, L. Blum, R. Seymour, J.F. et al.

Source: European Journal of Haematology. Jan2004, Vol. 72 Issue 1, p32-37. 6p.

Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation.

Authors: Biagi, J J Mileshkin, L Grigg, A P et al.

Source: Bone Marrow Transplantation. 12/15/2001, Vol. 28 Issue 12, p1145. 6p.

Successful Treatment of Rhinocerebral Zygomycosis Using Liposomal Nystatin.

Authors: Mileshkin, L. Slavin, M. Seymour, JF. et al.

Source: Leukemia & Lymphoma. Sep2001, Vol. 42 Issue 5, p1119. 5p.

Severe interstitial pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature.

Authors: Mileshkin, L Prince, H M Rischin, D et al.

Source: Bone Marrow Transplantation. 3/1/2001, Vol. 27 Issue 5, p559. 5p.

Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study.

Authors: Sivakumaran, T. Mileshkin, L. Grant, P. et al.

Source: Gynecologic Oncology. Jul2020, Vol. 158 Issue 1, p47-53. 7p.

Satisfaction with the decision to participate in cancer clinical trials is high, but understanding is a problem.

Authors: Jefford M Mileshkin L Matthews J et al.

Source: Supportive Care in Cancer. Mar2011, Vol. 19 Issue 3, p371-379. 9p.

LBA16 Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP)

Authors: Mileshkin, L. Bochtler, T. Pauli, C. et al.

Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS1254-S1255. 2p.

In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma.

Authors: Ritchie, D. Mileshkin, L. Wall, D. et al.

Source: Cancer Immunology, Immunotherapy. Feb2007, Vol. 56 Issue 2, p155-163. 9p. 4 Diagrams, 3 Charts.

519P Patterns of care and outcomes in carcinoma of unknown primary: A SEER-Medicare study.

Authors: Mileshkin, L. Bochtler, T. Beringer, A. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS459-S459. 1p.

452PD - Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated phase I dose-escalation/expansion results.

Authors: Voskoboynik, M. Mileshkin, L. Gan, H. et al.

Source: Annals of Oncology. 2019 Supplement 6, Vol. 30, pv167-v167. 1p.

Synchronous diagnosis of Hodgkin lymphoma and osteosarcoma.

Authors: Fon, A. Mileshkin, L. Slavin, J. et al.

Source: Internal Medicine Journal. Oct2007, Vol. 37 Issue 10, p731-732. 2p. 1 Color Photograph.

LBA33 ICON9: International phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy

Authors: Nicum, S. Ledermann, J.A. Mileshkin, L. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS1225-S1226. 2p.

Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide.

Authors: Prince, H. M. Schenkel, B. Mileshkin, L.

Source: Leukemia (08876924). Apr2007, Vol. 21 Issue 4, p818-820. 3p. 2 Cartoon or Caricatures.

9119 POSTER Combination of Pertuzumab and Erlotinib as 2nd-/3rd-Line (2/3L) Treatment for Patients (pts) With Metastatic Non-Small Cell Lung Cancer (NSCLC) – Safety and Anti-Tumour Activity by FDG-PET/CT Imaging Changes

Authors: Hughes, B. Mileshkin, L. Townley, P. et al.

Source: European Journal of Cancer. Sep2011 Supplement 1, Vol. 47, pS629-S629. 1p.

The Contribution of Cytotoxic Chemotherapy to the Management of Cancer

Authors: Mileshkin, L. Rischin, D. Prince, H.M. et al.

Source: Clinical Oncology. Jun2005, Vol. 17 Issue 4, p294-294. 1p.

Adjuvant trastuzumab in HER2-positive breast cancer.

Authors: Collins I Francis P Mileshkin L et al.

Source: New England Journal of Medicine. 2/16/2012, Vol. 366 Issue 7, p664-666. 4p.

An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009.

Authors: Lingaratnam, S. Slavin, M. A. Mileshkin, L. et al.

Source: Internal Medicine Journal. Jan2011, Vol. 41 Issue 1b, p110-120. 11p. 1 Chart, 4 Graphs.

Use of antibacterial prophylaxis for patients with neutropenia.

Authors: Slavin, M. A. Lingaratnam, S. Mileshkin, L. et al.

Source: Internal Medicine Journal. Jan2011, Vol. 41 Issue 1b, p102-109. 8p. 1 Chart.